BTK Inhibitor Acquired Resistance Panel-994
Test info
BTK acquired resistance
This panel detects mutations in BTK and PLC-gamma-2 which are associated with acquired ibrutinib resistance in certain B-cell neoplasms. This panel is appropriate for patients with B-cell neoplasms who have relapsed and/or show acquired (secondary) resistance after an initial response to BTK (Bruton tyrosine kinase) inhibitors.
Specimen
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
Lavender (EDTA), 4mL
Molecular Medicare billing request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Refrigerated - 72 hours
- Clotted specimens
- Frozen specimens
Performance
Molecular
Clinical and Interpretive info
Billing
81479
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.